INTRODUCTION
Biochemical tests are used for various purposes in clinical practice (e.g. diagnosis, screening, monitoring), but in every case a question, even if not posed formally, is being asked: for example, is my clinical diagnosis correct? does this patient have a condition that is not clinically apparent? is there objective evidence of a change in the patient's condition or of a response to treatment?
The conditions that must be satis®ed to generate a valid test result are well known. They are conventionally divided into pre-analytical, analytical and post-analytical. Unless a result is known to be valid, it is at best useless and at worse positively dangerous. A test result is of no value until it is applied to the relevent clinical problem. This means that it must be considered in relation to other information and lead to a clinical management decision ± whether this be to take some action or do nothing. The`other information' will include information about the patient and knowledge about the test itself, particularly its speci®city and sensitivity to answer the question that is being posed.
Most diagnostic clinical biochemistry laboratories offer a repertoire of well over a hundred tests. Some of these will be familiar to all doctors, but others are less so, either because they are relevant only to certain specialities, or because they have only been recently introduced.
A request to perform a biochemical test implies a request for a specialist opinion when this is required. The requester is asking the laboratory staff to bring their expertise to bear on the management of the patient. When the requesting clinician is familiar with the test, all that he may require is the result. Provided that this is reliable, he may require no further information to use it effectively. But there are many instances when the value of a result can be considerably enhanced if it is accompanied by a written comment that may indicate, for example, possible causes of an abnormality, options for further investigation or a need for immediate treatment.
It is neither practicable, nor appropriate, to comment on every report. It can reasonably be assumed that (for example) a renal physician will be familiar with the nuances of tests of renal function, or that any doctor can see that a result falls within a reference interval (although even the renal physician may not know the imprecision of a measurement of serum creatinine concentration and therefore not have a quantitative view of the signi®cance of a change).
WHEN ARE INTERPRETATIVE COMMENTS REQUIRED?
The Royal College of Pathologists has published guidelines for the provision of interpretative comments on biochemical reports, 1 and these have been adopted by CPA(UK) Ltd as part of their standards for accreditation. These guidelines indicate that whether a comment is required will depend upon:
the clinical details provided the clinical implication of the results the likely familiarity of the requesting clinician with the test(s) and its (their) interpretation.
The guidelines suggest that comments might be appropriate in the following circumstances: when a decision on management or treatment is indicated by the results in combination with the clinical details provided when a result is unexpected when a speci®c question has been posed but it is not obvious whether the results provide the answer when a clinician has requested a test with which he is not likely to be familiar.
WHO SHOULD COMMENT ON REPORTS?
Checking reports containing abnormal results, and commenting where necessary, is usually a function of a department's duty biochemist. 2 Staff involved in this usually include clinical biochemists with either medical or scientist backgrounds, and may also include senior medical laboratory scienti®c of®cers particularly in district general hospitals where numbers of the former staff groups may be very small. Given the importance of this function, we feel that only those appropriately qualifed (e.g. with knowledge base and experience at least equivalent to Part 1 of MRCPath or similar quali®cation) should comment unsupervised. Those without this should only comment under supervision; such staff should have an appropriate quali®cation con®rming possession of an adequate knowledge base (e.g. a taught MSc in Clinical Biochemistry), and must have had further formal training appropriate to clinical interpretation. 2 Some departments use standard computergenerated test comments for a few categories of results (e.g. relating HbA 1c concentration to state of glycaemic control, or relating progesterone concentration to ovulatory status). In our view, these rule-based comments are not strictly speaking interpretative comments: they are very limited in their applications; the algorithms on which they are based may be questionable; and critically they take no account of clinical information provided about the patient. However, further development and increasing sophistication may change our view on this.
PRACTICAL ISSUES
Three important, inter-related issues arise from these recommendations. These are: ®rst, the nature of the training required for the provision of clinically useful reports; second, the quality assurance of the provision; and third, how this activity should be audited. We have been prompted to consider these issues from analysing the comments sent to the Internet-based Cases for Comment'. 3 This consists of a series of clinical scenarios and biochemical data, mailed weekly to registrants, on which they are invited to comment as if they were reporting the results from their own laboratory. The author of Cases for Comment' (GC) anonymizes and summarizes the responses, which are then sent to a group of senior members of the profession (medically and scienti®cally quali®ed, working in academic and non-academic laboratories) who are invited to review the comments and score them for their appropriateness. The summarized comments and the experts' views on them are then posted on the Internet. 4 Perhaps surprisingly, some cases have elicited a wide range of opinion and comment even for super®cially straightforward patterns of abnormality, although, in many instances, there is a reassuring degree of agreement between the respondents and the views of the expert reviewers. Discrepancies are sometimes understandable differences of opinion, often apparently related to differing local practice. The detail of comments inevitably varies according to individuals' own expertise and experience. But some of the comments that are suggested stand out as being, at least in our view, inappropriate; some are potentially misleading.
COMMENTS RECEIVED ON`CASES FOR COMMENT'
We have selected some comments received on two`Cases for Comment' to illustrate the range of comments and some of our concerns. Our opinions are given in italics. Given the nature of personal opinion based on past experience, we accept that some will inevitably disagree with our opinions.
Case 1
A 46-year-old woman, seeing her family doctor. Clinical information:`On progesterone-only oral contraceptive. Amenorrhoea for 3 months.'
Serum FSH 32 U/L (reference values: follicular phase 2±11, ovulatory peak 5±34, luteal phase 1±8, menopausal 28±133). 
COMMENTARY
We must emphasize that, in general, there is considerable agreement between individual comments, and between these and the views of the expert reviewers. However, it is unusual for there not to be at least one discordant comment on every set of data, and in some cases there are several. We have not attempted to quantify these: participants are self-selected and vary in number from case to case.`Cases for Comment' is an arti®cial exercise and may not re¯ect actual practice. However, we suggest that the potential for similar comments to be made on reports being returned to clinicians should be a cause for concern. Inappropriate comments fall into several categories. suggested that the general practitioner should measure the haemoglobin. Suggesting the obvious may not endear us to our colleagues; suggesting that a primary care physician should measure the blood pressure of a patient with diabetes and microalbuminuria comes into the same category. 5. Comments that restate the obvious: respondents often comment on the presence of an abnormal result without commenting on its possible signi®cance.
DISCUSSION
We are not aware of any publications speci®cally addressing the issue of the quality of comments on biochemical reports, but it is clear from experience with`Cases for Comment' that inappropriate comments are sometimes made by both medical and scientist clinical biochemists working in teaching and non-teaching hospitals. We also know from the results of surveys that have used similar methodology (albeit paper-based rather than electronic) that we are not alone in identifying poor performance in clinical biochemistry interpretation: this has been reported both by the UK North East Thames Biochemistry Clinical Audit Steering Group (H Smith, personal communication, 2000) and the South Thames (East)
Chemical Pathology Audit Group (SK Bangert, personal communication, 2000). In specialized areas such as toxicology, 5 interpretation of results has sometimes been included as part of existing EQA. This has highlighted the importance of laboratory interpretation, and the importance to it of training and EQA has been stressed. Training in clinical interpretation is often provided informally, at the bench, or through study of case discussions or commentaries. The former approach is primarily directed towards the recognition of patterns of results in relation, where available, to whatever clinical information is provided. In theory it should be possible to test the interpretation against the clinical outcome but in practice this is either not possible, or is impractical. The cases that are followed up are likely to be the more unusual ones, which are not representative of the bulk of our work. Case discussions also tend to be based on relative rarities, but the outcome is usually known and the biochemical diagnosis, in retrospect at least, is clear-cut. Examinations such as the Part 1 in Chemical Pathology for the Membership of the Royal College of Pathologists include a data interpretation paper, but the cases are usually complex and designed to test an understanding of clinicopathological relationships as well as interpretational skills.
The clinical information provided on request forms ± if any ± is usually very limited and may be inappropriate to the question implicitly posed by the request. This itself poses formidable problems for the duty biochemist (interpretation of thyroid function tests is notorious in this regard), and absence of relevant clinical information may make a`no comment' response appropriate even when signi®cant and perhaps surprising test abnormalities are present (however, it is likely to be better practice in this situation to use a standard comment: please 'phone me if you wish to discuss these abnormalities further). In the absence of full clinical information, and the results of other investigations, there will often be several explanations for given patterns of biochemical data. Except in those cases when direct contact can be made with the clinician to discuss the patient, or when the outcome becomes known, there is no opportunity for the duty biochemist to learn through feedback, and so improve his/her interpretative skills. In addition, these skills include not only being able to decide on possible explanations for analytical results, but also being able to communicate an opinion effectively. To be useful, interpretative comments should be accurate and succinct; they should also be appropriate to the recipient's own likely knowledge and experience. We suggest that formal training in providing interpretative comments should be incorporated into training schemes for specialist registrars and trainee clinical scientists. It should concentrate as much on the wit of effective communication as the wisdom of interpretation.
Formal training is not suf®cient on its own to ensure good practice. There need also to be continual opportunities to re¯ect on performance. This may be a particular problem in small laboratories where the person responsible for providing intepretative comments may be working in relative isolation. Assessing the possible signi®cance of results and communicating this as appropriate is a vital part of the postanalytical phase, and we believe should be submitted to similar standards of quality assessment and audit as are rightly deemed essential for the analytical phase. An external quality assurance scheme is needed for interpretative comments, akin to the UK schemes now operating for histopathology and cytopathology, directed to individuals rather than to departments (although ensuring anonymity). Like the histopathology schemes, such a scheme could have a high educational value. It would also be valuable for selfaudit, in that practice would be surveyed, standards set and adherence to standards monitored.
There are many dif®culties in establishing such a scheme, the ®rst of which would be deciding on and setting appropriate standards. Unlike much of analytical QA, there is no gold standard. One cannot use a`comment mean' to de®ne best practice, and experience with`Cases for Comment' suggests that a precise consensus comment (a comment mode) seldom occurs. There is always likely to be scope for valid individual nuances of interpretation based on individual experience and expertise, and it may be debatable whether a standard should or even could be set. Based upon the very wide range of responses illustrated in the two example cases included here, we feel that a standard should be set, but that this should be based on appropriateness of response rather than any concept of correctness of response in relation to the actual outcome of a case. The best solution may be to borrow from the histopathologists and set the standard based on a pooled opinion from a group of experts ± a`core interpretation' which should be included in an appropriate response. The`experts' might be expected to comprise a group of experienced medical and non-medical clinical biochemists, from both teaching and district general hospitals, together with clinical users of our service.
A second dif®culty would be that such a scheme would be directed at individuals. Analytical QA schemes are directed towards the performance of the laboratory; assessing and reporting on biochemical data is an individual activity. Many of us might ®nd overt assessment of our individual performance intimidating, and what procedures would be required to notify and support`persistent poor performers'? A further problem is that it would be very dif®cult to devise a scheme in which the participant was not aware that the data being reported were part of the scheme. There would be an inevitable tendency to try to do well, and performance in the scheme might not be a valid indicator of day-to-day performance.
However, given the increasing importance of clinical governance ± the corporate responsibility for the quality of the service ± and increasing pressure for the monitoring of performance of individual medical consultants (which now extends to senior clinical scientists), it seems inevitable that, at some point, we will all need to become used to having our practice assessed rigorously and on a continuing basis. We trust that clinical biochemists are suf®ciently professional to accept this, and would welcome the establishment of a QA scheme for the interpretation of laboratory data. The scheme would be designed to improve rather than punish poor practice. We feel that this would be a valid and acceptable form of selfregulation. To this end, we are pleased to report that, during the preparation of this article, CPA(UK) Ltd announced that it has made funding available to establish a pilot EQAS for interpretative comments on clinical biochemistry reports. This will use a similar approach to`Cases for Comment' (but run as a web page rather than through an Internet discussion group); comments will be assessed through peer review. The primary purpose will be to provide education and feedback to all those engaged in commenting on clinical biochemistry reports.
